During the past decade, Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 11 clinical trials were completed, i.e. on average, 42.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 11 clinical trials were completed. i.e. 137.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj" #1 sponsor was "Celgene" with 5 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Shire" with 5 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Galapagos NV" with 3 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj" are "Ulcerative Colitis" (11 trials), "Crohn Disease" (6 trials), "Crohn's Disease" (6 trials), "Colitis, Ulcerative" (2 trials) and "Erosive Esophagitis" (1 trials). Many other conditions were trialed in "Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj" in a lesser frequency.

Most popular intervention types in "Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj" are "Drug" (25 trials), "Other" (7 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Filgotinib" (4 trials), "Ontamalimab" (4 trials), "Guselkumab" (3 trials) and "Ozanimod" (3 trials). Other intervention names were less common.

The vast majority of trials in "Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj" are 26 trials for "All" genders.

Currently, there are NaN active trials in "Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj". undefined are not yet recruiting, 9 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".